Xin Lang Cai Jing·2025-11-12 02:06Group 1 - The core viewpoint of the news highlights the stock performance and financial metrics of Zhaoyan New Drug, indicating a 99.22% increase in stock price year-to-date, with a recent slight decline in the last five and twenty trading days [1][2] - As of September 30, 2025, Zhaoyan New Drug reported a revenue of 985 million yuan, a year-on-year decrease of 26.23%, while the net profit attributable to shareholders increased by 214.79% to 80.71 million yuan [2] - The company has a market capitalization of 24.785 billion yuan and has seen significant trading activity, with a net inflow of 1.4684 million yuan from major funds [1] Group 2 - Zhaoyan New Drug's main business involves non-clinical safety evaluation services for drugs, accounting for 95.59% of its revenue, with clinical services and experimental model supply making up the remainder [1] - The company has distributed a total of 703 million yuan in dividends since its A-share listing, with 356 million yuan distributed in the last three years [3] - The number of shareholders increased by 57.61% to 96,500 as of September 30, 2025, indicating growing interest in the stock [2]